Phase 2 N=26 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=48 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Phase 2 N=73 Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Phase 2 N=68 Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
Marginal Zone Lymphoma · MZL
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment — 68.2 Percentage of participants — p=<0.0001
Phase 2 N=63 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma · B-cell Lymphoma
Primary: ORR (Overall Response Rate) — 46 Percentage of Participants
Phase 2 N=18 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants
Phase 2 N=27 Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Marginal Zone B-cell Lymphoma
Primary: Overall Response Rate — 81.8 Percentage
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=39 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Phase 3 N=454 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma
Lymphoma, Mucosa-Associated Lymphoid Tissue
Primary: Event-free-survival (EFS) — 51; 68; 51 percentage of patients
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Phase 2 N=4 Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
Marginal Zone Lymphoma · Follicular Lymphoma
Primary: Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction — 2 Participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
Phase 2 N=28 Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
Phase 2 N=11 Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
Untreated Mantle Cell Lymphoma
Primary: Number of Participants With Toxicity — 8 participants
Phase 2 N=86 Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Refractory Mantle Cell Lymphoma · Relapsed Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001
Phase 2 N=48 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma
Primary: Progression Free Survival (PFS) — 71.2; 54.2 percentage of participants
Phase 2 N=25 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=134 A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
Mantle Cell Lymphoma
Primary: Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC) — 29.9 percentage of participants
Phase 2 N=38 Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Phase 2 N=68 S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
Phase 2 N=110 A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Lymphoma
Primary: Objective Response Rate (ORR) Based on Lugano Classification Criteria — 50.0; 33.3; 57.1; 58.3 percentage of participants
Phase 2 N=48 A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Phase 2 N=70 Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…